Cerus reports Q2 EPS (3c), consensus (2c)

Reports Q2 revenue $52.4M, consensus $51.8M. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter’s commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generation, LED-based INT200 illumination device continues to surpass our expectations around performance and customer experience, and advancements in our product development pipeline are encouraging, including the early resubmission for RBC CE Mark and the recent DoD award for the CRYO-First study,” said William “Obi” Greenman, CEO. “In addition, the continued strong commercial and financial execution in Q2 resulted in record product sales, a year-over-year narrowing of net loss attributable to Cerus (CERS), and another quarter of positive non-GAAP adjusted EBITDA,” continued Greenman. “Given the anticipated sales trajectory, we are raising our full-year 2025 product revenue guidance today.”